OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients

Leuk Lymphoma. 2008 Nov;49(11):2222-3. doi: 10.1080/10428190802322893.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Benzamides
  • Drug-Related Side Effects and Adverse Reactions
  • Female
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Male
  • Middle Aged
  • Mutation, Missense* / drug effects
  • Octamer Transcription Factor-1 / genetics*
  • Piperazines / adverse effects*
  • Polymorphism, Single Nucleotide / drug effects
  • Pyrimidines / adverse effects*
  • Young Adult

Substances

  • Benzamides
  • Octamer Transcription Factor-1
  • POU2F1 protein, human
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate